Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EASYTRAK 4 STEERABLE LV lead · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| EASYTRAK 4 STEERABLE LV lead | DEVICE | - |
Inclusion Criteria: * Must receive a commercially available Guidant CRT-P or CRT-D device * Creatinine \< 2.5 mg/dL obtained no more than two weeks prior to enrollment * Age 18 or above, or of legal age to give informed consent specific to state and national law * Willing and capable of providing i...
Top 20 of 31 competitors
EASYTRAK 4 STEERABLE LV lead is used for heart failure. It is an investigational device being developed by Boston Scientific Corporation. The device is currently in Phase 2 clinical development, meaning it is still being studied and is not yet approved for commercial use.
EASYTRAK 4 STEERABLE LV lead is developed by Boston Scientific Corporation, a company publicly traded under the ticker symbol BSX. The device is being studied for the treatment of heart failure and is currently in Phase 2 clinical trials.
EASYTRAK 4 STEERABLE LV lead is in Phase 2 clinical development. It is an investigational device for heart failure and has completed one clinical trial. It has not been approved by regulatory authorities and remains under investigation.
EASYTRAK 4 STEERABLE LV lead has one completed clinical trial, identified as NCT00158964. This Phase 2 study enrolled 110 participants with heart failure in the United States. The trial was uncontrolled and did not use randomization or blinding.
EASYTRAK 4 STEERABLE LV lead is the full name of the device, and it may be referred to as EASYTRAK 4. The device is developed by Boston Scientific Corporation for heart failure and is currently in Phase 2 clinical development.